Celera and Medco Join Forces to Study Statin Adherence Following KIF6 Testing
September 23, 2009
Celera and Medco Join Forces to Study Statin Adherence Following KIF6 Testing
Researchers from Celera and Medco are investigating whether carriers of KIF6 who are made aware of their genetic risk factor and therapeutic advantage will stick to taking their statin drugs. But will it sway insurers?
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Medco Study Suggests Genetic Testing Improves Patient Compliance with Statins
October 19, 2011 / Pharmacogenomics Reporter - Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
March 28, 2012 / Pharmacogenomics Reporter - Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition
April 27, 2011 / Pharmacogenomics Reporter - Authors of Large Meta-Analysis Predict End of KIF6 Test, but Celera Calls Study Flawed
October 13, 2010 / Pharmacogenomics Reporter